Literature DB >> 10974429

Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study.

J F Cheer1, C A Marsden, D A Kendall, R Mason.   

Abstract

Cannabinoid compounds have been reported to excite ventral tegmental neurons through activation of cannabinoid CB1 receptors. More recently, biochemical and whole-cell voltage-clamp studies carried out on CB1-transfected AtT20 cells have shown a rapid desensitization of these receptors following activation of protein kinase C by 4-alpha-phorbol. To investigate the possible physiological correlates of this phenomenon, we have studied the effects of repeated cannabinoid treatment on ventral tegmental area dopaminergic neuronal firing in vitro. Rat brain slices containing the ventral tegmental area were used for single-unit extracellular recordings. Only neurons meeting established electrophysiological and pharmacological criteria for dopaminergic neurons were used in the study (firing neurons were detected either using tungsten or glass microelectrodes). The high-affinity cannabinoid agonist HU210 produced a concentration-dependent increase in firing (1-15 microM; EC(50) approximately 7 microM). Initial HU210 exposure produced a significant increase in cell firing rate in the ventral tegmental area, with a maximum approximately 3.5-fold increase over pre-drug basal firing; a subsequent exposure to HU210 produced an approximately threefold increase over basal firing. Nevertheless, the duration and onset of excitation produced by the cannabinoid differed significantly between the first and second exposures; the first excitation lasted significantly longer than the second and required less time to reach a comparable change in firing rate. The increases in firing rate and the time to return to basal firing were not significantly different between exposures. Furthermore, the cannabinoid antagonist SR141716A completely prevented the HU210-induced excitation whilst having no effect on its own, thus indicating a CB1-receptor mediated mechanism for the observed increase in firing. Ventral tegmental area neurons are also excited by the GABA(A) receptor antagonist bicuculline. To assess the role of GABA in cannabinoid-mediated excitation, HU210 was added in the presence of bicuculline. HU210 did not affect the initial bicuculline-induced increase in firing, suggesting different sites of action for the two compounds. Our data fail to support previously reported findings using repeated cannabinoid administration and cell preparations. The maintained increase in DA drive elicited by the potent cannabinoid agonist HU210 in the in vitro ventral tegmental circuit could explain some of the behavioural properties of cannabinoids, such as the lack of tolerance for the psychotropic effects of marijuana seen in human users.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974429     DOI: 10.1016/s0306-4522(00)00241-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  26 in total

1.  Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal.

Authors:  Taryn E Grieder; Olivier George; Huibing Tan; Susan R George; Bernard Le Foll; Steven R Laviolette; Derek van der Kooy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

2.  Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

Authors:  Angela M Lee; Erik B Oleson; Leontien Diergaarde; Joseph F Cheer; Tommy Pattij
Journal:  Basal Ganglia       Date:  2012-07-28

3.  Using dopamine research to generate rational cannabinoid drug policy.

Authors:  G C Loewinger; E B Oleson; J F Cheer
Journal:  Drug Test Anal       Date:  2012-09-19       Impact factor: 3.345

Review 4.  A brain on cannabinoids: the role of dopamine release in reward seeking.

Authors:  Erik B Oleson; Joseph F Cheer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

5.  Prenatal Ethanol Exposure Persistently Alters Endocannabinoid Signaling and Endocannabinoid-Mediated Excitatory Synaptic Plasticity in Ventral Tegmental Area Dopamine Neurons.

Authors:  Kathryn Hausknecht; Ying-Ling Shen; Rui-Xiang Wang; Samir Haj-Dahmane; Roh-Yu Shen
Journal:  J Neurosci       Date:  2017-05-05       Impact factor: 6.167

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens.

Authors:  Yolanda Mateo; Kari A Johnson; Dan P Covey; Brady K Atwood; Hui-Ling Wang; Shiliang Zhang; Iness Gildish; Roger Cachope; Luigi Bellocchio; Manuel Guzmán; Marisela Morales; Joseph F Cheer; David M Lovinger
Journal:  Neuron       Date:  2017-12-06       Impact factor: 17.173

8.  Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.

Authors:  Francesca M Filbey; Joseph P Schacht; Ursula S Myers; Robert S Chavez; Kent E Hutchison
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

Review 9.  Marijuana and cannabinoid regulation of brain reward circuits.

Authors:  Carl R Lupica; Arthur C Riegel; Alexander F Hoffman
Journal:  Br J Pharmacol       Date:  2004-08-16       Impact factor: 8.739

10.  Cannabinoids modulate ultrasound-induced aversive responses in rats.

Authors:  David P Finn; Maulik D Jhaveri; Simon R G Beckett; David A Kendall; Charles A Marsden; Victoria Chapman
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.